| |
n
|
Time-to-dropout with death as a competing risk
|
Death
|
|---|
|
SHR
|
(95%CI)
|
HR
|
(95%CI)
|
|---|
|
Study group
|
|
Intervention
|
150
|
1.23
|
(0.76, 1.99)
|
1.26
|
(0.84, 1.88)
|
|
Control
|
212
|
1
| |
1
| |
|
Age (years)
|
362
|
1.01
|
(0.99, 1.03)
|
1.02
|
(1.00, 1.03)
|
|
Study site
|
|
Study site 1
|
119
|
1
| | | |
|
Study site 2
|
98
|
1.77
|
(0.94, 3.33)
|
1.69
|
(0.99, 2.89)
|
|
Study site 3
|
145
|
1.60
|
(0.87, 2.93)
|
1.99
|
(1.22, 3.26)
|
|
Sex
|
|
Male
|
219
|
1.35
|
(0.82, 2.24)
|
0.75
|
(0.51, 1.11)
|
|
Female
|
143
|
1
| |
1
| |
|
Family status
|
|
Married
|
226
|
1.15
|
(0.50, 2.67)
|
1.68
|
(0.84, 3.38)
|
|
Single
|
44
|
1
| |
1
| |
|
Divorced/Widowed
|
63
|
2.71
|
(1.12, 6.56)
|
0.89
|
(0.36, 2.20)
|
|
Time since diagnosis
|
|
≤ 6 months
|
187
|
1
| |
1
| |
|
7–12 months
|
49
|
0.43
|
(0.17, 1.08)
|
1.06
|
(0.58, 1.93)
|
|
13–24 months
|
46
|
0.54
|
(0.22, 1.32)
|
1.53
|
(0.87, 2.67)
|
|
> 24 months
|
80
|
0.97
|
(0.54, 1.72)
|
1.33
|
(0.81, 2.19)
|
|
Diagnosis
|
|
Acute leukemia
|
69
|
1
| |
1
| |
|
Aggressive lymphoma
|
58
|
1.53
|
(0.64, 3.65)
|
0.55
|
(0.25, 1.23)
|
|
Malignant neoplasm of the bronchus and lungs
|
62
|
1.92
|
(0.84, 4.38)
|
1.78
|
(0.97, 3.27)
|
|
Metastatic colorectal cancer/colon carcinoma
|
78
|
1.39
|
(0.60, 3.21)
|
1.19
|
(0.64, 2.21)
|
|
Malignant neoplasm of the pancreas
|
32
|
1.94
|
(0.79, 4.77)
|
2.48
|
(1.27, 4.85)
|
|
Multiple myeloma and malignant plasma cell neoplasms
|
24
|
1.24
|
(0.40, 3.83)
|
0.56
|
(0.19, 1.65)
|
|
Metastasized malignant neoplasm of the breast
|
9
|
0.91
|
(0.11, 7.21)
|
0.41
|
(0.05, 3.10)
|
|
Others
|
30
|
2.13
|
(0.79, 5.74)
|
1.32
|
(0.58, 3.03)
|
|
Education
|
|
Low
|
29
|
1.85
|
(0.90, 3.81)
|
0.92
|
(0.39, 2.15)
|
|
Medium
|
101
|
1.27
|
(0.72, 2.25)
|
1.58
|
(1.02, 2.45)
|
|
High
|
206
|
1
| |
1
| |
|
Social support (OSSS-3)
|
|
Poor (3–8)
|
35
|
2.10
|
(1.01, 4.35)
|
0.83
|
(0.39, 1.79)
|
|
Moderate (9–11)
|
158
|
1.32
|
(0.74, 2.36)
|
0.87
|
(0.56, 1.36)
|
|
Strong (12–14)
|
139
|
1
| |
1
| |
- n Number of observation, SHR Sub-hazard ratio, HR Hazard ratio, CI Confidence Interval
